secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001171843-24-002570
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024
--------------------------------------------------------------------------------

- Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.
- Cash, cash equivalents and marketable securities $823.8M, up from $423.6M due to $432.3M net public offering.
- Phase 3 CSU studies to initiate summer 2024; 52-week Phase 2 CSU data expected H2 2024.
- Phase 2 CIndU enrollment completed (196 patients); 12-week data due H2 2024.
- Atopic dermatitis selected as fifth indication; Phase 2 study to start by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/0001171843-24-002570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184324002570/f8k_050624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer